Clinical trial · Interventional
Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer
A Phase II Study of Concurrent Nab-Paclitaxel, Carboplatin and Thoracic Radiotherapy in Local Advanced Squamous Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Nab-paclitaxel and carboplatin showed better treatment response compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer, especially for squamous cell cancer. The regimen of weekly nab-paclitaxel, carboplatin and concurrent radiotherapy was well tolerated in a phase I study. Given nab-paclitaxel, carboplatin and concurrent radiotherapy in patients with local advanced squamous cell lung cancer may have promising result.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Carcinoma, Squamous Cell | Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carboplatin | Drug | Carboplatin | ALIAS |
| Paclitaxel for Injection（Albumin Bound） | Drug | Paclitaxel | ALIAS |
| thoracic radiation therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- chemoradiotherapy
- description
- This is a single arm study with patients receiving nab-paclitaxel, carboplatin and thoracic radiotherapy.
- interventionNames
- Drug: Paclitaxel for Injection（Albumin Bound）
- Drug: carboplatin
- Radiation: thoracic radiation therapy
Primary outcomes (1)
- measure
- tumor response rate
- timeFrame
- one month after the end of all treatment
Secondary outcomes (3)
- measure
- progression-free survival
- timeFrame
- 2 years from patient enrollment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Scale. * Previously untreated, histological documented, inoperable stage IIIA or IIIB squamous cell carcinoma of lung, excluding those with pericardial, pleural effusion, and those with contralateral hilar or contralateral supraclavicular lymph nodes. * Patients must have measurable disease according to RECIST criteria, and all detectable tumor can be encompassed by radiation therapy fields. * Weight loss ≦ 5% in the previous six months. * Patient must have adequate blood, liver, lungs and kidney function within the requirements of this study. * Female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test. Male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose of study drug. * Patients must sign a study-specific informed consent form prior to study entry. Exclusion Criteria: * Complete tumor resection, recurrent disease, or those patients eligible for definitive surgery. * Previous chemotherapy or previous biologic response modifiers for current lung cancer. * Patient has previously had thoracic radiation therapy. * Prior or concurrent malignancy except non-melanomatous skin cancer unless disease-free for five years or more. * Serious concomitant disorders that would compromise the safety of the patient, or compromise the patient's ability to complete the study, at the discretion of the investigator. * History of significant neurological or mental disorder, including seizures or dementia.
References
Publications (0)
Data not yet available